Multiple Myeloma Clinical Trial 20193151

[LCID Study Number: 20193151]

S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

The purpose of this study is to compare therapies for Multiple Myeloma.

Disease/Condition: Multiple Myeloma

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2734

View NCT ID 04071457 on ClinicalTrials.gov
Protocol #: 20193151
Principal Investigator(s): Russell Baur
Study Coordinator(s): Deborah Gannon
Trial Phase: Sponsor Initiated Study Phase 3